|
|
- 2017
吡格列酮对PCOS卵巢颗粒细胞分泌雌激素的影响
|
Abstract:
摘要：目的 观察吡格列酮对多囊卵巢综合征(PCOS)患者卵巢颗粒细胞雌激素分泌功能和其上P450芳香化酶(P450arom)、胰岛素受体底物-1(IRS-1)和胰岛素受体底物-2(IRS-2)表达的影响。方法 对27例行体外受精-胚胎移植PCOS患者的颗粒细胞进行体外原代培养并分组，A组分别加入不同浓度(0、10、10？？2、10？？3、104nmol/L)吡格列酮、B组为不同浓度吡格列酮与卵泡刺激素(FSH，50ng/L)及C组为不同浓度吡格列酮与胰岛素样生长因子-Ⅰ(IGF-Ⅰ，50ng/L)。用放射免疫法检测培养上清液中雌二醇(E2)浓度，Real-time PCR法检测颗粒细胞上P450arom、IRS-1、IRS-2 mRNA的表达变化。结果 在A、B、C组中，人PCOS卵巢颗粒细胞培养48h的E2产生量差异有统计学意义(P<0.05)，吡格列酮各浓度组间P450arom mRNA表达量差异有统计学意义(P<0.05)，随着吡格列酮浓度的增加，E2水平和P450arom mRNA表达也随之下降；人PCOS卵巢颗粒细胞在相同浓度吡格列酮时，C组E2水平和P450arom mRNA表达明显高于B组(P<0.01)及A组(P<0.01)，B组E2产生量和P450arom mRNA？？表达高于A组，差异有统计学意义(P<0.05)；人PCOS卵巢颗粒细胞经不同浓度吡格列酮刺激48h，各浓度组间IRS-1、IRS-2 mRNA表达差异有统计学意义(P<0.05)，随着吡格列酮浓度的增加，IRS-1 mRNA表达随之下降，IRS-2 mRNA表达随之上升。结论 吡格列酮可能直接或间接通过对P450arom的抑制，减少E2的生成，改善颗粒细胞上IRS-1和IRS-2表达的失衡，抑制PCOS卵巢的局部胰岛素抵抗状态；吡格列酮可抑制FSH和IGF-Ⅰ刺激卵巢颗粒细胞分泌雌激素的功能。
ABSTRACT: Objective To observe the effects of pioglitazone on secretion of E2 and expressions of P450 aromatase (P450arom), insulin-receptor substrate-1 (IRS-1), and insulin-receptor substrate-2 (IRS-2) mRNA in polycystic ovary syndrome (PCOS) ovarian granulosa cells. Methods In this study, granulosa cells that were fertilization-embryo transferred from 27 PCOS patients were primary cultured in vitro with different concentrations of pioglitazone (0, 10, 10？？2, 10？？3 and 104nmol/L) (Group A), different concentrations of pioglitazone+FSH (50ng/L, Group B) and different concentrations of pioglitazone+insulin-like growth factor I (IGF-I, 50ng/L, Group C). Estradiol concentrations in the culture supernatant were detected by radioimmunoassay; P450arom, IRS-1 and IRS-2 mRNA expressions on granulosa cells were detected by Real-time PCR. Results The levels of E2 secreted by granulosa cells and the expression of P450arom mRNA on granulosa cells of PCOS for 48 hours were different among Groups A, B and C (P<0.05). With increase in pioglitazone concentration, the level of E2 and the expression of P450arom mRNA declined, some of which correlated negatively with the concentration of pioglitazone. Among these groups, the level of E2 secretion and the expression of P450arom mRNA were higher in Group C than in Group B (P<0.01) and Group A (P<0.01) at the same concentration of pioglitazone. The level of E2 secretion and the expression of P450arom mRNA were higher in Group B than in Group A (P<0.05) at the same concentration of pioglitazone. The expressions of IRS-1 and IRS-2 mRNA on granulosa cells of PCOS under pioglitazone stimulation for 48 hour were different among the groups of different pioglitazone concentrations (P<0.05). With increase
| [1] | DUMESIC DA, OBERFIELD SE, STENER-VICTORIN E, et al. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome[J]. Endocr Rev, 2015, 36(5):487-525. |
| [2] | ECKLUND LC, USADI RS. Endocrine and reproductive effects of polycystic ovarian syndrome[J]. Obstet Gynecol Clin North Am, 2015, 42(1):55-65. |
| [3] | 宋青，苟文丽. 吡格列酮对胰岛素抵抗型多囊卵巢综合征患者脂肪细胞因子的影响[J]. 西安交通大学学报(医学版), 2010, (2):227-230. |
| [4] | ISHA S, DHEER S. Conjugated linoleic acids attenuate FSH- and IGF1-stimulated cell proliferation; IGF1, GATA4, and aromatase expression; and estradiol-17b production in buffalo granulosa cells involving PPARg, PTEN, PI3K/Akt[J]. Reproduction, 2012, 144(3):373-383. |
| [5] | MAXIME R, MARION C, CHRISTELLE R, et al. Chemerin inhibits IGF-1-induced progesterone and estradiol secretion in human granulosa cells[J]. Hum Reprod, 2012, 27: 1790-1800. |
| [6] | ？sAKIR E, TOPALOGLU O, ？sOLAK BN, et al. Insulin-like growth factor 1, liver enzymes, and insulin resistance in patients with PCOS and hirsutism[J]. Turk J Med Sci, 2014, 44(5):781-786. |
| [7] | STUBBS SA, WEBBER LJ, STARK J, et al. Role of insulin-like growth factors in initiation of follicle growth in normal and polycystic human ovaries[J]. J Clin Endocrinol Metab, 2013, 98(8):3298-3305. |
| [8] | MAYER SB, EVANS WS, NESTLER JE. Polycystic ovary syndrome and insulin: Our understanding in the past, present and future[J]. Womens Health (Lond), 2015, 11(2):137-149. |
| [9] | YANG R, YANG S, LI R, et al. Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis[J]. Reprod Biol Endocrinol, 2016, 14(1):67-73. |
| [10] | NADERPOOR N, SHORAKAE S, COURTEN B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis[J]. Hum Reprod Update, 2015, 21(5):560-574. |
| [11] | The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) (2003)[J]. Fertil Steril, 2004, 81(1):19-25. |
| [12] | SON WY, DAS M, SHALOM-PAZ E, et al. Mechanisms of follicle selection and development[J]. Minerva Ginecol, 2011, 63(2):89-102. |
| [13] | GUPTA A, JAKUBOWICZ D, NESTLER JE. Pioglitazone therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome[J]. Metab Syndr Relat Disord, 2016, 14(8):391-396. |
| [14] | COPPS KD, WHITE MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2[J]. Diabetologia, 2012, 55(10):2565-2582. |
| [15] | WU S, DIVALL S, WONDISFORD F, et al. Reproductive tissues maintain insulin sensitivity in diet-induced obesity[J]. Diabetes, 2012, 61(1):114-123. |
